EcoDrugPlus

Matrix Metallopeptidase 1

Ensembl ID : ENSLLEG00000020615
Gene Symbol: MMP1
1 View Cross-references
366 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 13

Ensembl ID : ENSLLEG00000020531
Gene Symbol: MMP13
1 View Cross-references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 14

Ensembl ID : ENSLLEG00000010435
Gene Symbol: MMP14
1 View Cross-references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 2

Ensembl ID : ENSLLEG00000014792
Gene Symbol: MMP2
1 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 9

Ensembl ID : ENSLLEG00000030379
Gene Symbol: MMP9
1 View Cross-references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSLLEG00000021314
Gene Symbol: MTOR
1 View Cross-references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 1 Receptor

Ensembl ID : ENSLLEG00000028937
Gene Symbol: MC1R
1 View Cross-references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 3 Receptor

Ensembl ID : ENSLLEG00000027236
Gene Symbol: MC3R
1 View Cross-references
138 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 4 Receptor

Ensembl ID : ENSLLEG00000011826
Gene Symbol: MC4R
1 View Cross-references
121 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1a

Ensembl ID : ENSLLEG00000001410
Gene Symbol: MTNR1A
1 View Cross-references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1b

Ensembl ID : ENSLLEG00000026261
Gene Symbol: MTNR1B
1 View Cross-references
107 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSLLEG00000009136
Gene Symbol: MAPK1
1 View Cross-references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).